@ARTICLE{
author={Vesovic Natasa V,Tosic Natasa M,Karan-Djurasevic Teodora Z,Andric Zoran G,Zdravkovic Darko D,Pavlovic Sonja T,Jovanovic Dragana D},
year={2026},
title={Expression pattern of circulating long non-coding RNA GAS5 as a novel biomarker in non-small cell lung cancer patients},
journal={ARCHIVES OF MEDICAL SCIENCE},
volume={22},
number={1},
pages={469-475},
document_type={Article},
} 

@ARTICLE{
author={Zhang Jianjun,...,Andric Zoran G,...,(broj koautora 20)},
year={2025},
title={A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non-small cell lung cancer: HARMONi-3.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={43},
number={16_SUPPL},
pages={TPS8664-TPS8664},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Andric Zoran G,...,(broj koautora 16)},
year={2025},
title={Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer},
journal={CANCER TREATMENT AND RESEARCH COMMUNICATIONS},
volume={44},
number={},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Bozovic-Spasojevic Ivana M,Milovic-Kovacevic Marijana M,Lekic S,Cvetanovic A,Kolarov-Bjelobrk Ivana N,Lucic J,Andric Zoran G,Milenkovic D,...,Vukovic I,Petronijevic M,Calamac Marina D,Djurmez Ognjen,Djuric S,Perduv V,Radisavljevic M,Popovic Lazar S},
year={2025},
title={Real-world treatment patterns in patients with human epidermal growth factor receptor 2 (HER2) - positive early breast cancer in Serbia and Montenegro - HEReNA},
journal={BREAST},
volume={80},
number={},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Spigel David R,...,Chen Yuanbin,Navarro Alejandro,Chih Hsin Yang James,Stojanovic Goran,Jove Maria,...,Andric Zoran G,...,(broj koautora 17)},
year={2025},
title={Reply to P. de Boissieu et al},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={43},
number={3},
pages={-},
document_type={Letter},
} 

@ARTICLE{
author={Verschraegen C,Andric Zoran G,Moiseenko FV,Makharadze T,Oleksiienko A,Ruiz EP Yanez,Kim SH,Ahn K,Park TH,Ju HA,Baek EH,Kwon S,Lee SJ,Chang I,Kim SH,Kim HA,Lee E,Ohe Y},
year={2024},
title={3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer},
journal={ANNALS OF ONCOLOGY},
volume={35},
number={},
pages={S1648-S1649},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Kao SCH,Reck M,Liu SV,Dziadziuszko R,Hochmair MJ,Huemer F,Gilberto de Castro J,Bernabe Caro R,Kim SH,Kowalski DM,Andric Zoran G,Oancea M,Kaul M,Li H,Danner B,Lee MC,Nabet BY,Sugawara S},
year={2024},
title={Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ESSCLC) treated with atezolizumab (atezo)},
journal={ANNALS OF ONCOLOGY},
volume={35},
number={},
pages={S1638-S1638},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Tobias Joshua,...,Andric Zoran G,...,Nikolic Ivan V,Petrovic Zoran,...,(broj koautora 17)},
year={2024},
title={Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)},
journal={CLINICAL CANCER RESEARCH},
volume={30},
number={18},
pages={4044-4054},
document_type={Article},
} 

@ARTICLE{
author={Greil Richard,...,Andric Zoran G,...,(broj koautora 25)},
year={2024},
title={Tumor Treating Fields (TTFields) therapy with standard systemic therapy in metastatic non-small cell lung cancer following progression on or after platinum-based therapy: global, randomized, pivotal (phase 3) LUNAR study},
journal={ONCOLOGY RESEARCH AND TREATMENT},
volume={47},
number={},
pages={131-132},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Schuette Wolfgang,Andric Zoran G,...,(broj koautora 25)},
year={2024},
title={Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: IMbrella A extension study results},
journal={ONCOLOGY RESEARCH AND TREATMENT},
volume={47},
number={},
pages={124-125},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Tobias Joshua,...,Andric Zoran G,Petrovic Z,Nikolic Ivan V,...,(broj koautora 17)},
year={2024},
title={Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer - (HERIZON)},
journal={ANNALS OF ONCOLOGY},
volume={35},
number={},
pages={S886-S886},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Reck Martin,...,Andric Zoran G,...,(broj koautora 24)},
year={2024},
title={Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study},
journal={LUNG CANCER},
volume={196},
number={},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Weiss L,...,Andric Zoran G,...,(broj koautora 26)},
year={2024},
title={Pneumologische Onkologie Tumor Treating Fields (TTFields) therapy with standard systemic therapy in metastatic non-small cell lung cancer following progression on or after platinum-based therapy: global randomized, pivotal (phase 3) LUNAR study},
journal={PNEUMOLOGIE},
volume={78},
number={},
pages={S100-S100},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Spigel David R,...,Stojanovic Goran,...,Andric Zoran G,...,(broj koautora 17)},
year={2024},
title={RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={42},
number={19},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Reck Martin,...,Andric Zoran G,...,(broj koautora 18)},
year={2024},
title={Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={19},
number={2},
pages={297-313},
document_type={Article},
} 

@ARTICLE{
author={Leal Ticiana A,...,Andric Zoran G,...,(broj koautora 20)},
year={2024},
title={Tumor Treating Fields (TTFields) Therapy with Standard of Care in Metastatic Non-small Cell Lung Cancer Following Progression on or after Platinum Therapy: Global, Randomized, Pivotal Phase 3 LUNAR Study},
journal={INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS},
volume={118},
number={1},
pages={E9-E10},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Leal Ticiana A,...,Andric Zoran G,...,(broj koautora 20)},
year={2023},
title={Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={41},
number={17_SUPPL},
pages={LBA9005-LBA9005},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Andric Zoran G,...,Stojanovic Goran,Petrovic Marina D,...,(broj koautora 21)},
year={2023},
title={Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC},
journal={JTO CLINICAL AND RESEARCH REPORTS},
volume={4},
number={2},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Leal Ticiana A,...,Andric Zoran G,...,(broj koautora 25)},
year={2023},
title={TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={18},
number={11},
pages={S96-S97},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Liu SV,...,Andric Zoran G,...,(broj koautora 24)},
year={2023},
title={Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={18},
number={11},
pages={S44-S45},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Tobias Joshua,Kundi Michael,Garner-Spitzer E,Zielinski Christoph,Maglakelidze Marina,Andric Zoran G,Petrovic Z,Nagarkar R,Chawla T,Chong LO,Nixon B,Yavrom S,Ede NJ,Wiedermann Ursula},
year={2023},
title={HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome},
journal={ANNALS OF ONCOLOGY},
volume={34},
number={},
pages={S864-S864},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Kotecha R,...,Andric Zoran G,...,(broj koautora 20)},
year={2023},
title={Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study},
journal={ANNALS OF ONCOLOGY},
volume={34},
number={},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Leal Ticiana A,...,Andric Zoran G,...,(broj koautora 25)},
year={2023},
title={Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study},
journal={LANCET ONCOLOGY},
volume={24},
number={9},
pages={1002-1017},
document_type={Article},
} 

@ARTICLE{
author={Leal Ticiana A,...,Andric Zoran G,...,(broj koautora 20)},
year={2023},
title={Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={41},
number={17},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Tobias Joshua,Kundi Michael,Garner-Spitzer E,Zielinski Christoph,Maglakelidze Marina,Andric Zoran G,Petrovic Zeljko M,Nagarkar R,Chawla T,Chong LMO,Nixon B,Yavrom S,Ede NJ,Wiedermann Ursula},
year={2023},
title={HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome},
journal={ANNALS OF ONCOLOGY},
volume={34},
number={},
pages={S4-S4},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Rudin CM,Dowlati A,Chen Y,Navarro Mendivil AF,Yang JC-H,Stojanovic Goran,Rich P,Andric Zoran G,Wu Y-L,Chen H,Zhang L,Yeung S,Benzaghou FM,Paz-Ares L,Bunn PA},
year={2023},
title={RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={18},
number={4},
pages={S129-S130},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Maglakelidze Marina,Ryspayeva D,Andric Zoran G,Petrovic Zeljko M,Bulat IV,Nikolic Ivan V,Chawla T,Nagarkar R,Wiedermann Ursula,Blumenstein BA,Chong LMO,Ede NJ,Nixon B,Good AJ},
year={2022},
title={HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer},
journal={ANNALS OF ONCOLOGY},
volume={38},
number={9},
pages={S1460-S1460},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ohe Yuichiro,...,Andric Zoran G,...,(broj koautora 17)},
year={2022},
title={Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)},
journal={CANCER RESEARCH},
volume={82},
number={12},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ciardiello F,Feng Z,Smith NR,Andric Zoran G,Shell S,Yablonovitch A,Guezel G,Scheuenpflug J},
year={2022},
title={Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to firstline (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC)},
journal={ANNALS OF ONCOLOGY},
volume={33},
number={7},
pages={S1050-S1051},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Verschraegen Claire,Andric Zoran G,...,(broj koautora 20)},
year={2022},
title={1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer},
journal={ANNALS OF ONCOLOGY},
volume={33},
number={7},
pages={S1024-S1025},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Verschraegen Claire,Andric Zoran G,Moiseenko Fedor,Makharadze Tamta,Shevnya Sergii,Oleksiienko Alona,Ruiz Eduardo Yanez,Kim SungHyun,Ahn KeumYoung,Park TaeHong,Park Sijin,Ju Hana,Ohe Yuichiro},
year={2022},
title={Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial},
journal={BIODRUGS},
volume={36},
number={6},
pages={749-760},
document_type={Article},
} 

@ARTICLE{
author={Goel Shom,Tan Antoinette R,Rugo Hope S,Aftimos Philippe,Andric Zoran G,Beelen Andrew Paul,Zhang Jingshan,Yi John S,Malik Rajesh K,O'Shaughnessy Joyce},
year={2022},
title={Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2},
journal={FUTURE ONCOLOGY},
volume={18},
number={33},
pages={3701-3711},
document_type={Article},
} 

@ARTICLE{
author={Reck M,...,Andric Zoran G,...,(broj koautora 19)},
year={2022},
title={Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={17},
number={9},
pages={S39-S39},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Peters Solange,...,Andric Zoran G,...,(broj koautora 26)},
year={2022},
title={Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial},
journal={NATURE MEDICINE},
volume={28},
number={9},
pages={1831-+},
document_type={Article},
} 

@ARTICLE{
author={Perovic-Blagojevic Iva M,Vekic Jelena Z,Macut Djuro P,Ignjatovic Svetlana D,Miljkovic-Trailovic Milica M,Zeljkovic Aleksandra R,Spasojevic-Kalimanovska Vesna V,Bozic-Antic Ivana B,Bjekic-Macut Jelica D,Kastratovic-Kotlica Biljana A,Andric Zoran G,Ilic Dusan S,Kotur-Stevuljevic Jelena M},
year={2022},
title={Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia},
journal={BRITISH JOURNAL OF NUTRITION},
volume={128},
number={4},
pages={604-612},
document_type={Article},
} 

@ARTICLE{
author={Weiss Jared,Goldschmidt Jerome,Andric Zoran G,Dragnev Konstantin H,Gwaltney Chad,Skaltsa Konstantina,Pritchett Yili,Antal Joyce M,Morris Shannon R,Daniel Davey},
year={2021},
title={Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies},
journal={CLINICAL LUNG CANCER},
volume={22},
number={5},
pages={449-460},
document_type={Article},
} 

@ARTICLE{
author={Jassem Jacek,...,Andric Zoran G,...,(broj koautora 19)},
year={2021},
title={Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={16},
number={11},
pages={1872-1882},
document_type={Article},
} 

@ARTICLE{
author={Bjekic-Macut Jelica D,Vukasin Tamara,Velija-Asimi Zelija,Burekovic Azra,Zdravkovic Marija D,Andric Zoran G,Brankovic Marija S,Crevar-Marinovic Slobodanka,Madic Tatjana,Stanojlovic Olivera P,Milutinovic Danijela V,Livadas Sarantis,Mastorakos George},
year={2021},
title={Polycystic Ovary Syndrome: A Contemporary Clinical Approach},
journal={CURRENT PHARMACEUTICAL DESIGN},
volume={27},
number={36},
pages={3812-3820},
document_type={Review},
} 

@ARTICLE{
author={Goel Shom,O'Shaughnessy Joyce,Tan Antoinette R,Milev-Krastev Boris,Rugo Hope S,Aftimos Philippe Georges,Yardley Denise A,Andric Zoran G,Wolfgang Curt Douglas,Sorrentino Jessica,Tao Wenli,Beelen Andrew Paul,Malik Rajesh K,Jain Sarika},
year={2021},
title={Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={39},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Laeufle Rita,...,Andric Zoran G,...,Nikolic Ivan V,...,Radosavljevic Davorin Z,...,(broj koautora 16)},
year={2021},
title={HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={39},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Trukhin Dmytro,Poddubskaya Elena,Andric Zoran G,Bondarenko Igor N,Shevnia Serhii,Zaric Bojan,Bellala Ravishankar,Charoentum Chaiyut,Perez Luis,Bullo Felicitas,Garcia Fernanda},
year={2021},
title={Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={39},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Andric Zoran G,Ceric Timur,Rancic Milan H,Jakopovic Marko,Aix S Ponce,Ramlau Rodryg,Ulanska M,Caldwell C,Ferrari D,Annis A,Vukovic V,Zaric Bojan},
year={2021},
title={A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression},
journal={ANNALS OF ONCOLOGY},
volume={32},
number={},
pages={S1166-S1166},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Dziadziuszko R,...,Andric Zoran G,...,(broj koautora 20)},
year={2021},
title={Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C},
journal={ANNALS OF ONCOLOGY},
volume={32},
number={},
pages={S950-S951},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Abramson V,...,Andric Zoran G,Milovic-Kovacevic Marijana M,Trifunovic Jasna D,...,(broj koautora 16)},
year={2021},
title={A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancer},
journal={ANNALS OF ONCOLOGY},
volume={32},
number={},
pages={S619-S619},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Maglakelidze Marina,...,Andric Zoran G,Nikolic Ivan V,...,Radosavljevic Davorin Z,Petrovic Zoran,...,(broj koautora 17)},
year={2021},
title={A Phase 1b/2 Open-Label Study with Randomization in Phase 2 of Imu-131 Her2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients with Her2/Neu Overexpressing Metastatic Or Advanced Adenocarcinoma of the Stomach Or Gastroesophageal Junction.},
journal={CANCER RESEARCH},
volume={81},
number={13},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Syrigos Konstantinos,Abert Istvan,Andric Zoran G,Bondarenko Igor N,Dvorkin Mikhail,Galic Kristina,Galiulin Rinat,Kuchava Vladimer,Sriuranpong Virote,Trukhin Dmytro,Zhavrid Edvard,Fu Dongyue,Kassalow Laurent M,Jones Stephanie,Bashir Zahid},
year={2021},
title={Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)},
journal={BIODRUGS},
volume={35},
number={4},
pages={417-428},
document_type={Article},
} 

@ARTICLE{
author={Maglakelidze Marina,...,Andric Zoran G,Nikolic Ivan V,...,Radosavljevic Davorin Z,Petrovic Zeljko M,...,(broj koautora 16)},
year={2021},
title={HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction},
journal={ANNALS OF ONCOLOGY},
volume={32},
number={},
pages={S154-S154},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Trukhin Dmytro,...,Andric Zoran G,...,(broj koautora 19)},
year={2021},
title={Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)},
journal={BIODRUGS},
volume={35},
number={4},
pages={429-444},
document_type={Article},
} 

@ARTICLE{
author={Andric Zoran G,...,Stojanovic Goran,Petrovic Marina D,...,(broj koautora 20)},
year={2021},
title={First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={16},
number={4},
pages={S753-S754},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 20)},
year={2021},
title={IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={16},
number={3},
pages={S224-S225},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Hart Lowell L,Ferrarotto Renata,Andric Zoran G,Beck Thaddeus J,Subramanian Janakiraman,Radosavljevic Davorin Z,Zaric Bojan,Hanna Wahid T,Aljumaily Raid,Owonikoko Taofeek K,Verhoeven Didier,Xiao Jie,Morris Shannon R,Antal Joyce M,Hussein Maen A},
year={2021},
title={Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study},
journal={ADVANCES IN THERAPY},
volume={38},
number={1},
pages={350-365},
document_type={Article},
} 

@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 21)},
year={2020},
title={Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110},
journal={SWISS MEDICAL WEEKLY},
volume={},
number={},
pages={31S-32S},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Andric Zoran G,Ceric Timur,Stanetic Mirko,Rancic Milan H,Jakopovic Marko,Aix S Ponce,Ramlau Rodryg,Smit E,Ulanska M,Caldwell C,Ferrari D,Annis A,Vukovic V,Zaric Bojan},
year={2020},
title={Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924},
journal={EUROPEAN JOURNAL OF CANCER},
volume={138},
number={},
pages={S5-S5},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Kostic Sanja V,Murtezani Zafir,Andric Zoran G,Ivanovic Nebojsa S,Kozomara Zoran K,Kostic Marko I,Milicic Vesna M,Kocic Sanja S},
year={2020},
title={Assessment of age-related influences on the quality of life of breast cancer patients before and after surgical treatment},
journal={VOJNOSANITETSKI PREGLED},
volume={77},
number={9},
pages={908-916},
document_type={Article},
} 

@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 22)},
year={2020},
title={Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC},
journal={NEW ENGLAND JOURNAL OF MEDICINE},
volume={383},
number={14},
pages={1328-1339},
document_type={Article},
} 

@ARTICLE{
author={Millan Susana,Trukhin Dmytro,Kolesnik Oleksii,Poddubskaya Elena,Andric Zoran G,Bondarenko Igor N,Shevnia Serhii,Bullo Felicitas,Sarnago Cristina},
year={2020},
title={Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={38},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Jared Weiss,Jerome Goldschmidt,Andric Zoran G,Konstantin Dragnev H,Yili Pritchett,Shannon Morris R,Rajesh Malik K,Davey Daniel B},
year={2020},
title={Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={38},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 20)},
year={2020},
title={Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC},
journal={JOURNAL FOR IMMUNOTHERAPY OF CANCER},
volume={8},
number={},
pages={A1-A1},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Reinmuth Niels,...,Andric Zoran G,...,(broj koautora 20)},
year={2020},
title={Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC},
journal={ONCOLOGY RESEARCH AND TREATMENT},
volume={43},
number={},
pages={232-233},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Mansfield AS,...,Andric Zoran G,...,(broj koautora 19)},
year={2020},
title={Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial},
journal={ANNALS OF ONCOLOGY},
volume={31},
number={2},
pages={310-317},
document_type={Article},
} 

@ARTICLE{
author={Macut Djuro P,Mladenovic Violeta S,Bjekic-Macut Jelica D,Livadas Sarantis,Stanojlovic Olivera P,Hrncic Dragan R,Rasic-Markovic Aleksandra,Vojnovic-Milutinovic Danijela D,Andric Zoran G},
year={2020},
title={Hypertension in Polycystic Ovary Syndrome: Novel Insights},
journal={CURRENT HYPERTENSION REVIEWS},
volume={16},
number={1},
pages={55-60},
document_type={Review},
} 

@ARTICLE{
author={Perovic-Blagojevic Iva M,Ignjatovic Svetlana D,Macut Djuro P,Kotur-Stevuljevic Jelena M,Bozic-Antic Ivana B,Vekic Jelena Z,Bjekic-Macut Jelica D,Kastratovic-Kotlica Biljana A,Andric Zoran G,Ilic Dusan S},
year={2019},
title={Relationship between distribution of LDL subfractions and NAFLD in PCOS - Effect on CV risk},
journal={CLINICA CHIMICA ACTA},
volume={493},
number={},
pages={S340-S340},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Herbst Roy S,...,Andric Zoran G,...,(broj koautora 20)},
year={2019},
title={Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study},
journal={ANNALS OF ONCOLOGY},
volume={30},
number={},
pages={62-63},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Siefker-Radtke Arlene O,Lugowska Iwona,Tupikowski Krzysztof,Andric Zoran G,Rezazadeh-Kalebasty A,Curigliano Giuseppe,Vaena Daniel A,Vogl FD,Currie Graeme,Abella S,Kelly William Kevin},
year={2019},
title={Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22},
journal={ANNALS OF ONCOLOGY},
volume={30},
number={},
pages={365-365},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Spigel David R,...,Andric Zoran G,...,(broj koautora 20)},
year={2019},
title={IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC},
journal={ANNALS OF ONCOLOGY},
volume={30},
number={},
pages={915-915},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Hart Lowell L,Andric Zoran G,...,Radosavljevic Davorin Z,Jovanovic Dragana,...,Samarzija Miroslav,Zaric Bojan,...,(broj koautora 20)},
year={2019},
title={Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={37},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Siefker-Radtke Arlene O,Currie Graeme,Abella Esteban,Vaena Daniel A,Kalebasty Arash Rezazadeh,Curigliano Giuseppe,Tupikowski Krzysztof,Andric Zoran G,Lugowska Iwona,Kelly William Kevin},
year={2019},
title={FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={37},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Macut Djuro P,Bjekic-Macut Jelica D,Livadas Sarantis,Stanojlovic Olivera P,Hrncic Dragan R,Rasic-Markovic Aleksandra,Vojnovic-Milutinovic Danijela D,Mladenovic Violeta S,Andric Zoran G},
year={2018},
title={Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome},
journal={CURRENT PHARMACEUTICAL DESIGN},
volume={24},
number={38},
pages={4593-4597},
document_type={Review},
} 

@ARTICLE{
author={Andric Zoran G},
year={2018},
title={Lung cancer vaccine: Experiences in Serbia},
journal={ANNALS OF ONCOLOGY},
volume={29},
number={},
pages={166-166},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Perovic-Blagojevic Iva M,Ignjatovic Svetlana D,Macut Djuro P,Kotur-Stevuljevic Jelena M,Bozic-Antic Ivana B,Vekic Jelena Z,Bjekic-Macut Jelica D,Kastratovic-Kotlica Biljana A,Andric Zoran G,Ilic Dusan S},
year={2018},
title={Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and Its Relationship with Obesity},
journal={JOURNAL OF MEDICAL BIOCHEMISTRY},
volume={37},
number={4},
pages={476-485},
document_type={Article},
} 

@ARTICLE{
author={Schwartzberg Lee Steven,Roeland E,Andric Zoran G,Kowalski Dariusz,Radic J,Voisin Daniel,Rizzi Giada,Navari R,Gralla Richard J,Karthaus Meinolf},
year={2018},
title={Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy},
journal={ANNALS OF ONCOLOGY},
volume={29},
number={7},
pages={1535-1540},
document_type={Article},
} 

@ARTICLE{
author={Schwartzberg Lee Steven,Andric Zoran G,Kowalski Dariusz,Voisin Daniel,Rizzi Giada,Karthaus Meinolf},
year={2017},
title={Phase III safety evaluation of intravenous NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron, over multiple cycles},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={35},
number={31},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Schwartzberg Lee Steven,Andric Zoran G,Kowalski Dariusz,Voisin Daniel,Rizzi Giada,Karthaus Meinolf},
year={2017},
title={Phase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron},
journal={ANNALS OF ONCOLOGY},
volume={28},
number={},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Djedovic J,Andric Zoran G},
year={2017},
title={Vemurafenib in metastatic melanoma treatment - Case report},
journal={JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY},
volume={31},
number={},
pages={67-68},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Bozic-Antic Ivana B,Ilic Dusan S,Bjekic-Macut Jelica D,Bogavac Tamara,Vojnovic-Milutinovic Danijela D,Kastratovic-Kotlica Biljana A,Milic Natasa M,Stanojlovic Olivera P,Andric Zoran G,Macut Djuro P},
year={2016},
title={Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome},
journal={EUROPEAN JOURNAL OF ENDOCRINOLOGY},
volume={175},
number={6},
pages={551-560},
document_type={Article},
} 

@ARTICLE{
author={Bjekic-Macut Jelica D,Radosavljevic Vojislav,Andric Zoran G,Ilic Dusan S,Stanojlovic Olivera P,Vojnovic-Milutinovic Danijela D,Bozic-Antic Ivana B,Zdravkovic Marija D,Hinic Sasa B,Macut Djuro P,Zarkovic Milos P},
year={2016},
title={Cortisol Response to Low-Dose (1 mu g) Acth Stimulation for the Prediction of Outcome in Patients with Systemic Inflammatory Response Syndrome},
journal={JOURNAL OF MEDICAL BIOCHEMISTRY},
volume={35},
number={4},
pages={428-435},
document_type={Article},
} 

@ARTICLE{
author={Macut Djuro P,Tziomalos Konstantinos,Bozic-Antic Ivana B,Bjekic-Macut Jelica D,Katsikis Ilias,Papadakis Efstathios,Andric Zoran G,Panidis Dimitrios},
year={2016},
title={Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome},
journal={HUMAN REPRODUCTION},
volume={31},
number={6},
pages={1347-1353},
document_type={Article},
} 

@ARTICLE{
author={Ramalingam Suresh S,...,Zaric Bojan,Andric Zoran G,...,(broj koautora 22)},
year={2015},
title={A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)},
journal={ANNALS OF ONCOLOGY},
volume={26},
number={8},
pages={1741-1748},
document_type={Article},
} 

@ARTICLE{
author={Macut Djuro P,Bacevic Marina,Bozic-Antic Ivana B,Bjekic-Macut Jelica D,Civcic Milorad,Erceg Snjezana,Vojnovic-Milutinovic Danijela D,Stanojlovic Olivera P,Andric Zoran G,Kastratovic-Kotlica Biljana A,Sukilovic Tijana},
year={2015},
title={Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure},
journal={INTERNATIONAL JOURNAL OF ENDOCRINOLOGY},
volume={},
number={},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Sipetic-Grujicic Sandra B,Murtezani Zafir,Neskovic-Konstantinovic Zora B,Marinkovic Jelena M,Kovcin Vladimir N,Andric Zoran G,Kostic Sanja V,Ratkov Isidora S,Maksimovic Jadranka M},
year={2014},
title={Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia},
journal={ASIAN PACIFIC JOURNAL OF CANCER PREVENTION},
volume={15},
number={7},
pages={3233-3238},
document_type={Article},
} 

@ARTICLE{
author={Ramalingam Suresh S,...,Zaric Bojan,...,Andric Zoran G,...,(broj koautora 26)},
year={2013},
title={Galaxy-1: Randomized Phase Ii Study of Docetaxel with Or Without Ganetespib in Advanced Lung Adenocarcinoma: Results in Biomarker Sub-Groups and All Adenocarcinoma Patients.},
journal={JOURNAL OF THORACIC ONCOLOGY},
volume={8},
number={},
pages={S139-S139},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ramalingam Suresh S,...,Andric Zoran G,...,Zaric Bojan,...,Vukovic Vojislav M,...,(broj koautora 20)},
year={2013},
title={A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={31},
number={18},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Ramalingam Suresh S,...,Andric Zoran G,...,Zaric Bojan,Ceric Timur,...,Vukovic Vojislav M,...,(broj koautora 20)},
year={2013},
title={A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1)},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={31},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Fennell DA,Goss GD,Andric Zoran G,Bondarenko Igor N,Zaric Bojan,Ceric Timur,Poddubskaya Elena,Teofilovici F,Guo W,Ramalingam Suresh S},
year={2013},
title={Ganetespib in combination with docetaxel versus docetaxel alone in second line adenocarcinoma patients with KRAS mutations and elevated LDH levels},
journal={EUROPEAN JOURNAL OF CANCER},
volume={49},
number={},
pages={S801-S801},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Jovanovic Dragana D,Secen Nevena M,Murtezani Zafir,Rancic Milan H,Kacar-Kukric Vesna D,Velinovic Marta,Tepavac Ana,Budisin Evica S,Andric Zoran G,Vukobradovic-Djoric Nevena},
year={2013},
title={Analysis of clinicopathological characteristics of 982 lung cancer patients and subsequent treatment Epidemiology study},
journal={EUROPEAN RESPIRATORY JOURNAL},
volume={42},
number={},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Andric Zoran G,Havel L,Di Hariry I,Vukovic Vojislav M,Teofilovici F,Guo W,Mulcahey S,Bradley R,Ceric Timur},
year={2012},
title={Quality of Life Analysis in the Galaxy Trialtm (Nct01348126): a Randomized Phase Iib/Iii Study of Ganetespib (Sta-9090) in Combination with Docetaxel Versus Docetaxel Alone in Patients with Stage Iiib Or Iv Nsclc},
journal={ANNALS OF ONCOLOGY},
volume={23},
number={},
pages={436-436},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Jovanovic Dusan,Secen Nevena M,Murtezani Zafir,Rancic Milan H,Kacar-Kukric Vesna D,Velinovic Milos M,Tepavac Aleksandar,Budisin Evica S,Andric Zoran G,Vukobradovic-Djoric Nevena},
year={2012},
title={Characteristics of 982 Lung Cancer Patients in Serbia According to the Who/Iaslc Classification of Lung Cancers and Subsequent Treatment Avatar Epidemiology Study},
journal={ANNALS OF ONCOLOGY},
volume={23},
number={},
pages={428-428},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Andric Zoran G,Randjelovic Tomislav D,Kovcin Vladimir N,Gutovic Jasmina,Crevar Slobodanka,Murtezani Zafir,Kostic Sanja V},
year={2012},
title={Evaluation of the Efficacy and Toxicity of Protocol Cisplatin, 5-Fluorouracil, Leucovorin Compared to Protocol Fluorouracil, Doxorubicin and Mitomycin C in Locally Advanced and Metastatic Gastric Cancer},
journal={SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO},
volume={140},
number={5-6},
pages={305-312},
document_type={Article},
} 

@ARTICLE{
author={Kovcin Vladimir N,Manojlovic Nebojsa S,Jovanovic Dusan,Vrbic Svetislav,Andric Zoran G,Nikolic Ivan V,Pantelic Aleksandra,Ursulovic Tamara B},
year={2011},
title={The Impact of Capecitabine Dose Modification to Duration of Treatment in Patients with Metastatic Colorectal Cancer - First Results From Axiom Trial},
journal={ANNALS OF ONCOLOGY},
volume={22},
number={},
pages={v101-v102},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Kovcin Vladimir N,Jovanovic Dusan,Manojlovic Nebojsa S,Vrbic Svetislav,Andric Zoran G,Nikolic Ivan V,Pantelic Aleksandra,Radosavljevic Davorin Z},
year={2011},
title={Prospective Evaluation of Response and Conversion-to-resectability Rate in Patients with Metastatic Colorectal Cancer After 4 Cycles Capox/folfox Plus Bevacizumab - Updated Results From Relevant Trial},
journal={ANNALS OF ONCOLOGY},
volume={22},
number={},
pages={v101-v101},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Radic S,Markovic M,Kovcin Vladimir N,Andric Zoran G,Manojlovic Nebojsa S,Jovanovic Dusan,Nikolic Ivan V,Pantelic Aleksandra,Popov Ivan P},
year={2010},
title={Relevant: Prospective Evaluation of Efficacy and Safety of Bevacizumab Therapy in Metastatic Colorectal Carcinoma; Interim Analysis of Resecatability Rate},
journal={ANNALS OF ONCOLOGY},
volume={21},
number={},
pages={217-217},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Andric Zoran G,Kovcin Vladimir N,Gutovic Jasmina,Murtezani Zafir,Kostic Sanja V,Pantic Branislav},
year={2006},
title={Sequential chemotherapy with vinorelbin plus carboplatin followed by radiotherapy versus radiotherapy alone in elderly patients with locally advanced non small cell lung cancer/NSCLC},
journal={ANNALS OF ONCOLOGY},
volume={17},
number={},
pages={228-228},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Andric Zoran G,Murtezani Zafir,Kovcin Vladimir N,Gutovic Jasmina,Kostic Sanja V},
year={2006},
title={5-fluorouracil (5-FU),folinic acid (FA) and oxaliplatin (FUFOX) as second chemotherapy in patients with metastatic colorectal cancer (MCRC)},
journal={ANNALS OF ONCOLOGY},
volume={17},
number={},
pages={66-67},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Radosavljevic Vojislav,Kovcin Vladimir N,Andric Zoran G,Petrovic N,Ponomarev Dimitrije R},
year={2000},
title={Comparison of the therapeutic effect of mitomycin-C ifosfamide-cisplatin (MIC) against mitomycin-C vinblastine-cisplatin (MVP) regimen in non-small cell lung cancer (NSCLC).},
journal={ANNALS OF ONCOLOGY},
volume={11},
number={},
pages={117-117},
document_type={Meeting Abstract},
}